BPC-157 + KPV is a two-peptide vendor product that pairs a stable gastric pentadecapeptide studied for cytoprotection and tissue repair with the C-terminal tripeptide of alpha-melanocyte-stimulating hormone, studied for anti-inflammatory signalling. Researchers look at the pairing because the two components are described in separate literatures that both centre on the gut mucosa and on injury-associated inflammation. This monograph covers each component's evidence and the fact that the combination itself has not been studied.
Composition
The product contains two distinct peptides: BPC-157, a synthetic 15-amino-acid peptide (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) corresponding to a partial fragment of a protein identified in human gastric juice [1], and KPV, the tripeptide Lys-Pro-Val, which is the C-terminal three-residue fragment of α-MSH [2]. There is no single molecular weight or formula for the product; each peptide keeps its own identity and must be verified separately. The listings currently tracked in VialTalk's catalog for this blend are encapsulated products rather than lyophilized vials; VialTalk does not reproduce per-unit amounts. The proportion of each peptide in a given product is set by the vendor and is not standardised across the market.
What each component contributes
BPC-157. The mechanisms described in the literature are hypothesised rather than settled; the most consistently reported are promotion of angiogenesis via the VEGFR2 pathway and modulation of the nitric oxide system [1]. A 2025 narrative review describes overlapping pathways including VEGFR2, Akt-eNOS nitric oxide signalling and ERK1/2, and characterises the compound's effects as angiogenic, fibroblast-activating and anti-inflammatory in animal models [3]. In cultured rat tendon fibroblasts, BPC-157 did not directly increase proliferation but increased cell survival under oxidative stress, cell migration and spreading, with increased FAK and paxillin phosphorylation [4]. A 2026 cell-based study reported that intracellular BPC-157 engages the E3 ligase adaptor FBXO22, stabilising the transcription factor BACH1 and enhancing vascular-regeneration processes [5].
KPV. KPV is reported to carry the anti-inflammatory activity of the parent α-MSH peptide without the pigmentation effects [2]. In immortalised human bronchial epithelial cells, KPV inhibited NF-κB signalling and IL-8 and eotaxin secretion; the effect was associated with nuclear import of KPV, IκBα stabilisation and suppressed nuclear translocation of the p65RelA subunit — consistent with an intracellular mode of action [6]. In a rat TNBS colitis model, KPV delivered in a mucosa-adherent hydrogel alleviated colitis and supported recovery of the epithelial barrier [7].
The rationale for pairing them. Both literatures converge on gastrointestinal mucosal injury and inflammation: BPC-157 through cytoprotection and repair-associated angiogenesis [1][3], KPV through suppression of NF-κB-driven inflammatory signalling [6][7]. This is a hypothesis, not evidence of additive or synergistic action.
Combination evidence — the honest boundary
No study of BPC-157 and KPV given together was found. A PubMed search combining the two names (BPC-157/BPC 157/BPC157 with KPV/Lys-Pro-Val) returned a single record: a 2026 review of the FDA Pharmacy Compounding Advisory Committee's evaluation of synthetic peptides, which lists BPC-157 and KPV among the compounds discussed — it is a regulatory review, not a combination experiment [12]. The VialTalk research library holds one document addressing the three-way pairing of KPV, BPC-157 and TB-500; it is an OSF-posted synthesis project, not peer-reviewed experimental work, and its own description states that each peptide has been studied independently in preclinical contexts [11].
Each component's own evidence base is thin in humans:
- BPC-157 in humans. There are no completed, published controlled human trials [1]. A systematic review found that 35 of its 36 included studies were preclinical [8]. A 2025 narrative review identified only three human pilot studies, none rigorous or large-scale [3]; one is a two-participant safety pilot without a control arm [9]. A randomised, placebo-controlled Phase 2 trial in acute hamstring strain is registered and recruiting, with no results posted [10].
- BPC-157 in animals and cells. The bulk of the literature is rodent work, dominated by a small number of research groups [1], plus cell studies such as [4] and [5].
- KPV in humans. There is little substantial human clinical-trial data and KPV is not an approved drug [2].
- KPV in animals and cells. The evidence comes from rodent colitis models [7] and human cell-line work [6].
The published work covers each peptide only on its own [1][2][11]. Nothing is known about pharmacokinetic interaction, stability of the two peptides in a shared formulation, or whether either alters the other's activity. Any claim that the pair outperforms either component alone is unsupported.
Research context
Each component has been studied separately in gut and mucosal-inflammation models [1][2]. It is a reduced form of the three-peptide BPC-157 + TB-500 + KPV blend, without TB-500. Neither blend has been studied as a fixed combination.
Storage and handling
Follow the vendor's storage statement for the product format; keep peptide material sealed, dry, cool and protected from light. A blend is only as stable as its least-stable component, so default to the more conservative storage window of the two.
Quality and COA considerations
A meaningful COA for this product must confirm identity of both peptides by mass spectrometry and report purity for each by HPLC — a single "blend purity" line does not show that both are present. BPC-157 sequence-incorrect and under-filled product is a known market problem [1]; KPV, as a simple tripeptide, is straightforward to verify [2]. Demand a per-component content breakdown, not just a total. For capsules, the COA should state whether the finished product or the raw peptide was tested.
Key references
[1] VialTalk monograph — BPC-157 — https://vialtalk.com/forum/peptide-research-library/bpc-157-research-monograph-structure-mechanism-evidence
[2] VialTalk monograph — KPV — https://vialtalk.com/forum/peptide-research-library/kpv-research-monograph-alpha-msh-tripeptide-anti-inflammatory
[3] Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing (2025) — https://pubmed.ncbi.nlm.nih.gov/40789979/
[4] BPC 157 tendon healing: outgrowth, cell survival and migration (rat tendon fibroblasts) — https://pubmed.ncbi.nlm.nih.gov/21030672/
[5] BPC157 drives angiogenesis through FBXO22-dependent stabilization of BACH1 (2026) — https://pubmed.ncbi.nlm.nih.gov/41606641/
[6] Mechanism of KPV action in human bronchial epithelial cells — https://pubmed.ncbi.nlm.nih.gov/22837805/
[7] A KPV-binding double-network hydrogel restores gut mucosal barrier in an inflamed colon — https://pubmed.ncbi.nlm.nih.gov/35245681/
[8] Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review — https://pubmed.ncbi.nlm.nih.gov/40756949/
[9] BPC-157 human safety pilot study, two participants (2025) — https://pubmed.ncbi.nlm.nih.gov/40131143/
[10] NCT07437547 — BPC 157 for hamstring strain (Phase 2, recruiting) — https://clinicaltrials.gov/study/NCT07437547
[11] Precision Micro-Peptides: KPV, BPC-157 and TB-500 (OSF project) — https://doi.org/10.17605/osf.io/kypv3
[12] Willis & Vu, Int J Pharm Compd 2026 — Synthetic Peptides in Pharmacy Compounding — https://pubmed.ncbi.nlm.nih.gov/42752426/
Research-use note: This monograph is an educational summary of the published literature on BPC-157 and KPV. The fixed BPC-157 + KPV combination has not been studied in any published human or animal study known to VialTalk, and neither peptide is an approved drug. Nothing here is medical advice or a usage recommendation.